OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

Tepotinib is an oral, once daily, highly selective, potent MET inhibitor approved for MET exon 14 (METex14) skipping NSCLC based mainly on Cohort A of the multi-cohort Phase II VISION study. We report primary analysis (>9-months’ follow-up) of the independent confirmatory Cohort C; data cut-off February 20, 2022.